Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 241 to 247 of 247 entries
Sorted by: Best Match Show Resources per page
[Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores].

Bulletin du cancer

Perrier A, Hainaut P, Lamy PJ, Guenoun A, Nguyen DP, Guerber F, Troalen F, Denis JA, Boissan M.
PMID: 35012767
Bull Cancer. 2022 Jan 07; doi: 10.1016/j.bulcan.2021.11.010. Epub 2022 Jan 07.

In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the development of high-throughput sequencing, have led to the emergence...

Cite
Perrier A, Hainaut P, Lamy PJ, et al. Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques. [Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores]. Bull Cancer. 2022;doi: 10.1016/j.bulcan.2021.11.010.
Perrier, A., Hainaut, P., Lamy, P. J., Guenoun, A., Nguyen, D. P., Guerber, F., Troalen, F., Denis, J. A., & Boissan, M. (2022). Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques. [Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores]. Bulletin du cancer, . https://doi.org/10.1016/j.bulcan.2021.11.010
Perrier, Alexandre, et al. "Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques." [Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores]. Bulletin du cancer vol. (2022). doi: https://doi.org/10.1016/j.bulcan.2021.11.010
Perrier A, Hainaut P, Lamy PJ, Guenoun A, Nguyen DP, Guerber F, Troalen F, Denis JA, Boissan M. Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques. [Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores]. Bull Cancer. 2022 Jan 07; doi: 10.1016/j.bulcan.2021.11.010. Epub 2022 Jan 07. French. PMID: 35012767.
Copy Download .nbib Format: NLM
Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study.

Chest

Marjanovic N, Boisson M, Asehnoune K, Foucrier A, Lasocki S, Ichai C, Leone M, Pottecher J, Lefrant JY, Falcon D, Veber B, Chabanne R, Drevet CM, Pili-Floury S, Dahyot-Fizelier C, Kerforne T, Seguin S, de Keizer J, Frasca D, Guenezan J, Mimoz O.
PMID: 33727034
Chest. 2021 Aug;160(2):499-508. doi: 10.1016/j.chest.2021.03.007. Epub 2021 Mar 13.

BACKGROUND: Ventilator-associated pneumonia (VAP) is the most frequent health care-associated infection in severely ill patients, and aspiration of contaminated oropharyngeal content around the cuff of the tracheal tube is the main route of contamination.RESEARCH QUESTION: Is continuous regulation of...

Cite
Marjanovic N, Boisson M, Asehnoune K, et al. Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study. Chest. 2021;160(2):499-508doi: 10.1016/j.chest.2021.03.007.
Marjanovic, N., Boisson, M., Asehnoune, K., Foucrier, A., Lasocki, S., Ichai, C., Leone, M., Pottecher, J., Lefrant, J. Y., Falcon, D., Veber, B., Chabanne, R., Drevet, C. M., Pili-Floury, S., Dahyot-Fizelier, C., Kerforne, T., Seguin, S., de Keizer, J., Frasca, D., Guenezan, J., Mimoz, O. (2021). Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study. Chest, 160(2), 499-508. https://doi.org/10.1016/j.chest.2021.03.007
Marjanovic, Nicolas, et al. "Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study." Chest vol. 160,2 (2021): 499-508. doi: https://doi.org/10.1016/j.chest.2021.03.007
Marjanovic N, Boisson M, Asehnoune K, Foucrier A, Lasocki S, Ichai C, Leone M, Pottecher J, Lefrant JY, Falcon D, Veber B, Chabanne R, Drevet CM, Pili-Floury S, Dahyot-Fizelier C, Kerforne T, Seguin S, de Keizer J, Frasca D, Guenezan J, Mimoz O. Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study. Chest. 2021 Aug;160(2):499-508. doi: 10.1016/j.chest.2021.03.007. Epub 2021 Mar 13. PMID: 33727034.
Copy Download .nbib Format: NLM
[DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].

Bulletin du cancer

Broussais F, Bay JO, Boissel N, Baruchel A, Arnulf B, Morschhauser F, Robin M, Guepin GR, Moreau P, Gandemer V, Manier S, Leguay T, Nguyen Quoc S, Schwartzmann A, Houot R, Le Gouill S.
PMID: 34920797
Bull Cancer. 2021 Oct;108(10):S143-S154. doi: 10.1016/j.bulcan.2021.07.002.

CAR-T Cells have opened new doors for cellular immunotherapies and provides new therapeutic options for patients with refractory B-cell malignancies, B-cell acute lymphoblastic leukemia and diffuse large B-cel lymphoma. CAR-T Cells have benefited from an accelerated approval procedure in...

Cite
Broussais F, Bay JO, Boissel N, et al. DESCAR-T, le registre national des patients traités par CAR-T Cells. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France]. Bull Cancer. 2021;108(10):S143-S154doi: 10.1016/j.bulcan.2021.07.002.
Broussais, F., Bay, J. O., Boissel, N., Baruchel, A., Arnulf, B., Morschhauser, F., Robin, M., Guepin, G. R., Moreau, P., Gandemer, V., Manier, S., Leguay, T., Nguyen Quoc, S., Schwartzmann, A., Houot, R., & Le Gouill, S. (2021). DESCAR-T, le registre national des patients traités par CAR-T Cells. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France]. Bulletin du cancer, 108(10), S143-S154. https://doi.org/10.1016/j.bulcan.2021.07.002
Broussais, Florence, et al. "DESCAR-T, le registre national des patients traités par CAR-T Cells." [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France]. Bulletin du cancer vol. 108,10 (2021): S143-S154. doi: https://doi.org/10.1016/j.bulcan.2021.07.002
Broussais F, Bay JO, Boissel N, Baruchel A, Arnulf B, Morschhauser F, Robin M, Guepin GR, Moreau P, Gandemer V, Manier S, Leguay T, Nguyen Quoc S, Schwartzmann A, Houot R, Le Gouill S. DESCAR-T, le registre national des patients traités par CAR-T Cells. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France]. Bull Cancer. 2021 Oct;108(10):S143-S154. doi: 10.1016/j.bulcan.2021.07.002. French. PMID: 34920797.
Copy Download .nbib Format: NLM
SARS-CoV-2 vaccination efficacy on hospitalisation and variants.

Anaesthesia, critical care & pain medicine

Rozencwajg S, Blet A, Lamer A, Boisson M, Clavier T, Abou-Arab O.
PMID: 33901708
Anaesth Crit Care Pain Med. 2021 Apr 23;100867. doi: 10.1016/j.accpm.2021.100867. Epub 2021 Apr 23.

No abstract available.

Cite
Rozencwajg S, Blet A, Lamer A, et al. SARS-CoV-2 vaccination efficacy on hospitalisation and variants. Anaesth Crit Care Pain Med. 2021;100867doi: 10.1016/j.accpm.2021.100867.
Rozencwajg, S., Blet, A., Lamer, A., Boisson, M., Clavier, T., Abou-Arab, O. (2021). SARS-CoV-2 vaccination efficacy on hospitalisation and variants. Anaesthesia, critical care & pain medicine, 100867. https://doi.org/10.1016/j.accpm.2021.100867
Rozencwajg, Sacha, et al. "SARS-CoV-2 vaccination efficacy on hospitalisation and variants." Anaesthesia, critical care & pain medicine vol. (2021): 100867. doi: https://doi.org/10.1016/j.accpm.2021.100867
Rozencwajg S, Blet A, Lamer A, Boisson M, Clavier T, Abou-Arab O. SARS-CoV-2 vaccination efficacy on hospitalisation and variants. Anaesth Crit Care Pain Med. 2021 Apr 23;100867. doi: 10.1016/j.accpm.2021.100867. Epub 2021 Apr 23. PMID: 33901708; PMCID: PMC8062906.
Copy Download .nbib Format: NLM
Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index.

Clinical and experimental rheumatology

Avouac J, Degrave R, Vergneault H, Combier A, Wanono S, Boisson M, Frantz C, Allanore Y.
PMID: 33938795
Clin Exp Rheumatol. 2021 Apr 23; Epub 2021 Apr 23.

OBJECTIVES: We aimed to estimate the amount of scarring in the liver with the fibrosis-4 (FIB-4) index in patients with rheumatoid arthritis (RA) with special interest in methotrexate (MTX) influence.METHODS: This was a cross-sectional monocentric study including successive RA...

Cite
Avouac J, Degrave R, Vergneault H, et al. Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index. Clin Exp Rheumatol. 2021;
Avouac, J., Degrave, R., Vergneault, H., Combier, A., Wanono, S., Boisson, M., Frantz, C., & Allanore, Y. (2021). Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index. Clinical and experimental rheumatology, .
Avouac, Jérôme, et al. "Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index." Clinical and experimental rheumatology vol. (2021).
Avouac J, Degrave R, Vergneault H, Combier A, Wanono S, Boisson M, Frantz C, Allanore Y. Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index. Clin Exp Rheumatol. 2021 Apr 23; Epub 2021 Apr 23. PMID: 33938795.
Copy Download .nbib Format: NLM
Post-exercise accumulation of interstitial lung water is greater in hypobaric than normobaric hypoxia in adults born prematurely.

Respiratory physiology & neurobiology

Debevec T, Poussel M, Osredkar D, Willis SJ, Sartori C, Millet GP.
PMID: 34890833
Respir Physiol Neurobiol. 2021 Dec 07;297:103828. doi: 10.1016/j.resp.2021.103828. Epub 2021 Dec 07.

We aimed to gauge the interstitial lung water accumulation following moderate-intensity exercise under normobaric and hypobaric hypoxic conditions in a group of preterm born but otherwise healthy young adults. Sixteen pre-term-born individuals (age = 21±2yrs.; gestational age = 29±3wk.;...

Cite
Debevec T, Poussel M, Osredkar D, et al. Post-exercise accumulation of interstitial lung water is greater in hypobaric than normobaric hypoxia in adults born prematurely. Respir Physiol Neurobiol. 2021;297:103828doi: 10.1016/j.resp.2021.103828.
Debevec, T., Poussel, M., Osredkar, D., Willis, S. J., Sartori, C., & Millet, G. P. (2021). Post-exercise accumulation of interstitial lung water is greater in hypobaric than normobaric hypoxia in adults born prematurely. Respiratory physiology & neurobiology, 297103828. https://doi.org/10.1016/j.resp.2021.103828
Debevec, Tadej, et al. "Post-exercise accumulation of interstitial lung water is greater in hypobaric than normobaric hypoxia in adults born prematurely." Respiratory physiology & neurobiology vol. 297 (2021): 103828. doi: https://doi.org/10.1016/j.resp.2021.103828
Debevec T, Poussel M, Osredkar D, Willis SJ, Sartori C, Millet GP. Post-exercise accumulation of interstitial lung water is greater in hypobaric than normobaric hypoxia in adults born prematurely. Respir Physiol Neurobiol. 2021 Dec 07;297:103828. doi: 10.1016/j.resp.2021.103828. Epub 2021 Dec 07. PMID: 34890833.
Copy Download .nbib Format: NLM
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.

JAMA oncology

Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P.
PMID: 34455431
JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939.

IMPORTANCE: Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases.OBJECTIVE: To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients...

Cite
Siva S, Bressel M, Mai T, et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1476-1485doi: 10.1001/jamaoncol.2021.2939.
Siva, S., Bressel, M., Mai, T., Le, H., Vinod, S., de Silva, H., Macdonald, S., Skala, M., Hardcastle, N., Rezo, A., Pryor, D., Gill, S., Higgs, B., Wagenfuehr, K., Montgomery, R., Awad, R., Chesson, B., Eade, T., Wong, W., Sasso, G., De Abreu Lourenco, R., Kron, T., Ball, D., Neeson, P. (2021). Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA oncology, 7(10), 1476-1485. https://doi.org/10.1001/jamaoncol.2021.2939
Siva, Shankar, et al. "Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,10 (2021): 1476-1485. doi: https://doi.org/10.1001/jamaoncol.2021.2939
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. PMID: 34455431; PMCID: PMC8404145.
Copy Download .nbib Format: NLM
Showing 241 to 247 of 247 entries